Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521

Watchlist Manager
Zhejiang Huahai Pharmaceutical Co Ltd Logo
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Watchlist
Price: 17.79 CNY 0.68% Market Closed
Market Cap: 26.6B CNY

Zhejiang Huahai Pharmaceutical Co Ltd
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zhejiang Huahai Pharmaceutical Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Gross Profit
ÂĄ5.2B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
13%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Gross Profit
ÂĄ12B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Gross Profit
ÂĄ3.6B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Gross Profit
ÂĄ26.5B
CAGR 3-Years
14%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Gross Profit
ÂĄ11.6B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Gross Profit
ÂĄ5.5B
CAGR 3-Years
111%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Huahai Pharmaceutical Co Ltd
Glance View

Market Cap
26.6B CNY
Industry
Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co., Ltd., nestled in the vibrant economic landscape of China, has crafted a reputation as a pioneering force in the pharmaceutical industry. The company began its journey with a modest ambition: to establish itself as a reliable provider of Active Pharmaceutical Ingredients (APIs). Over the years, Huahai has broadened its horizons beyond APIs, expanding into the realm of finished dosage forms. This strategic diversification has enabled the company to control the entire value chain—from manufacturing raw pharmaceutical compounds to delivering final medicines ready for consumption. This integrated approach not only enhances quality control but also fortifies their market presence globally, allowing Huahai to cement its status as a formidable player in pharmaceutical exports. What sets Zhejiang Huahai apart is its steadfast commitment to innovation and compliance with international standards. The company channels considerable resources into research and development, focusing on therapeutic areas such as cardiovascular and central nervous system disorders. This devotion to R&D not only fuels the pipeline of new products but also enhances profitability by ensuring a steady stream of high-demand medications. Furthermore, Huahai's strategic partnerships with global pharmaceutical giants shape a dual-edged strategy of market expansion and shared expertise. By working closely with partners worldwide, Huahai ensures that its products remain at the cutting edge of medical advancements while maintaining regulatory compliance in diverse markets. This approach is what powers Huahai's steady revenue growth and robust competitive edge in the ever-evolving pharmaceutical sector.

Intrinsic Value
25.19 CNY
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Zhejiang Huahai Pharmaceutical Co Ltd's Gross Profit?
Gross Profit
5.2B CNY

Based on the financial report for Sep 30, 2025, Zhejiang Huahai Pharmaceutical Co Ltd's Gross Profit amounts to 5.2B CNY.

What is Zhejiang Huahai Pharmaceutical Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
13%

Over the last year, the Gross Profit growth was -10%. The average annual Gross Profit growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been 4% over the past three years , 6% over the past five years , and 13% over the past ten years .

Back to Top